Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Long-term thalidomide for actinic prurigo.

S A Yong-Gee¹, J B Muir

¹Department of Dermatology, Mater Misericordiae Hospital, South Brisbane, Queensland, Australia.

The Australasian Journal of Dermatology

|March 21, 2002

Summary

This case study highlights the long-term safety of thalidomide for treating actinic prurigo. A patient experienced sustained relief from photosensitive lesions for over two decades without adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Severe acute radiation dermatitis in a patient with argyria.

Case reports in oncological medicine·2014

Same author

PERFORATED TYPHOID ULCER: NOTES ON THREE SUCCESSFUL CASES.

British medical journal·2010

Same author

REMOVAL OF AN ASCARIS FROM THE COMMON BILE DUCT.

British medical journal·2010

Same author

Nucleotide for Leucopenia in Pneumococcal Peritonitis.

British medical journal·2010

Same author

Objective assessment of port-wine stains following treatment with the 585 nm pulsed dye laser.

The Australasian journal of dermatology·2002

Same author

Erythema multiforme: a case with unusual histopathological features.

The Australasian journal of dermatology·2000

Area of Science:

Dermatology
Immunogenetics

Background:

Actinic prurigo is a rare, severe photosensitivity disorder.
Human Leukocyte Antigen (HLA) associations, particularly HLA-DR4, are noted in actinic prurigo.

Observation:

A 35-year-old male presented at age 8 with recurrent, pruritic, papulovesicular lesions triggered by light exposure.
Diagnosis of actinic prurigo was confirmed by HLA-DR4, specifically the DRB1*0407 subtype.

Findings:

Thalidomide treatment initiated at age 11 led to rapid lesion resolution.
Long-term maintenance therapy (50 mg/day for 23 years, cumulative dose >400g) effectively controlled photosensitivity.
No adverse effects, including neuropathy, were observed during the extended treatment period.

Implications:

This case demonstrates the potential for safe and effective long-term thalidomide use in managing severe actinic prurigo.
Highlights the importance of HLA genotyping in diagnosing and managing this condition.
Suggests thalidomide as a viable therapeutic option for recalcitrant cases of actinic prurigo.

Related Experiment Videos